Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Research & Development (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Research & Development data on record, last reported at $208000.0 in Q3 2025.

  • For Q3 2025, Research & Development fell 97.8% year-over-year to $208000.0; the TTM value through Sep 2025 reached $22.0 million, down 64.0%, while the annual FY2024 figure was $56.6 million, 44.34% down from the prior year.
  • Research & Development reached $208000.0 in Q3 2025 per FBIO's latest filing, down from $8.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $58.6 million in Q4 2021 and bottomed at $208000.0 in Q3 2025.
  • Average Research & Development over 5 years is $22.9 million, with a median of $22.7 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 7961.6% in 2021, then tumbled 97.8% in 2025.
  • A 5-year view of Research & Development shows it stood at $58.6 million in 2021, then tumbled by 40.02% to $35.2 million in 2022, then crashed by 60.06% to $14.0 million in 2023, then crashed by 31.02% to $9.7 million in 2024, then plummeted by 97.85% to $208000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $208000.0 in Q3 2025, $8.1 million in Q2 2025, and $3.9 million in Q1 2025.